mk-2214

MK-2214 is an investigational monoclonal antibody developed by Merck for the treatment of Alzheimer's disease and mild cognitive impairment. It acts as a tau antagonist, targeting microtubule-associated protein tau to inhibit its pathological aggregation in the brain. The drug is administered via intravenous infusion and is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in adults with mild cognitive impairment or mild-to-moderate Alzheimer's disease[2][3][5]. The primary goal of these studies is to determine whether MK-2214 achieves sufficient concentrations in cerebrospinal fluid that may be therapeutically relevant[2][5].